Summary
New Zealand’s Medsafe and Pharmac announced that from February 2026, GPs and nurse practitioners will be able to initiate ADHD treatment for adults without a specialist referral — a significant expansion of prescribing authority. Currently, GPs can only prescribe stimulants to patients already diagnosed and initiated by a paediatrician or psychiatrist.
Key Points
- Change effective February 2026 (delayed from July 2025 to allow workforce preparation and address methylphenidate supply concerns).
- Over 940 people and organizations responded to the consultation; majority supportive.
- For children and adolescents, nurse practitioners working in child health or mental health services will be able to diagnose and initiate treatment.
- Decision follows removal of two-yearly renewal criteria for ADHD medicines.
- Implementation includes a clinical framework setting principles for diagnosis and treatment quality.
- Methylphenidate supply concerns were raised in consultation and factored into the delayed timeline.
Newsletter Angles
- Part of a global pattern: Australia (NSW, Queensland, WA) and New Zealand are all expanding GP prescribing authority for ADHD. This is a direct response to specialist bottleneck — a structural access failure being resolved from the bottom up.
- Contrast with the U.S.: the DEA’s Schedule II classification creates the opposite dynamic — tighter control, not expanded access. Different regulatory philosophies, different outcomes.
- The supply concern footnote is significant: even where prescribing authority expands, methylphenidate shortages could limit real-world impact.
Entities Mentioned
- Medsafe — New Zealand medicines regulator; approved prescribing change
- Pharmac — NZ pharmaceutical funder; issued the announcement
Concepts Mentioned
- ADHD Medication Shortage — NZ methylphenidate supply concerns parallel US Adderall shortage
- Therapist Shortage — specialist bottleneck driving the GP-authority expansion
Notes
Official government press release — high factual reliability. NZ context; not directly applicable to US policy but useful as international comparison. The February 2026 implementation date means this is forward-looking policy at time of source writing.